Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Goldman Sachs Starts Atara Biotherapeutics (ATRA) at Neutral
November 10, 2014 7:20 AM ESTGoldman Sachs initiated coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Neutral rating and a price target of $30.00.
Analyst Navdeep Singh said, "Atara is an early-stage biotech developing (1) PINTA 745 for kidney dialysis patients who suffer from muscle wasting and (2) STM 434 for advanced ovarian... More
Jefferies Starts Atara Biotherapeutics (ATRA) at Buy
November 10, 2014 7:13 AM ESTJefferies initiates coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Buy rating and a price target of $35.00.
Analyst Ryan Martins states, "ATRA has a proven management team with extensive experience in licensing and developing products. We believe ATRA's two lead clinical products, PINTA 745 and STM 434,... More
